Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Comparison of Two Artificial Liver Support Treatments for Acute-on-Chronic Liver Failure

7 novembre 2026 aggiornato da: Shan Zhong, The Second Affiliated Hospital of Chongqing Medical University

A Multicenter, Prospective, Non-Inferiority Cohort Study of Plasma Exchange Combined With Double Plasma Molecular Adsorption System (PE+DPMAS) Versus Plasma Exchange Combined With Continuous Renal Replacement Therapy (PE+CRRT) in Patients With Acute-on-Chronic Liver Failure

This study compares two blood-filtering treatment approaches used in adults with acute-on-chronic liver failure, a sudden worsening of liver function in people with long-term liver disease.

Both approaches include plasma exchange, which removes and replaces the liquid part of the blood. One approach combines plasma exchange with a system that uses filters to remove certain substances from the blood. The other combines plasma exchange with continuous kidney support therapy, which helps remove waste and excess fluid.

The treating doctors and patients decide which treatment to use as part of routine care. The study does not assign treatment. The researchers will follow participants to find out how many are alive without a liver transplant 90 days after joining the study. They will also compare complications, blood test results, and safety outcomes. Participants may choose to join a separate part of the study that collects blood and stool samples.

Panoramica dello studio

Stato

Non ancora reclutamento

Descrizione dettagliata

This multicenter, prospective, observational cohort study uses a noninferiority design to compare two artificial liver support strategies in adults with acute-on-chronic liver failure: plasma exchange plus double plasma molecular adsorption system (PE plus DPMAS) and plasma exchange plus continuous renal replacement therapy (PE plus CRRT).

The planned enrollment is 400 participants across two hospitals, with a target of 200 participants in each cohort. Treatment decisions are made in routine clinical practice by the treating clinicians in consultation with patients. Participants are grouped according to the treatment they receive. The study protocol does not assign treatment, and there is no randomization.

The primary outcome is 90-day transplant-free survival, measured from enrollment. The first occurrence of death from any cause or liver transplantation is counted as an event. An independent committee blinded to treatment group adjudicates the primary outcome events. The analysis will use propensity score matching to address measured differences between the two cohorts.

An optional exploratory substudy plans to enroll 120 consenting participants. Research blood samples will be used for peripheral blood mononuclear cell single-cell RNA sequencing and plasma-based omics analyses. Stool samples will be used to characterize the gut microbiome. Participants may decline the substudy and still participate in the main cohort.

Tipo di studio

Osservativo

Iscrizione (Stimato)

400

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Cina, 400010
        • The Second Affiliated Hospital of Chongqing Medical University
        • Contatto:
    • Zhejiang
      • Hangzhou, Zhejiang, Cina, 310023
        • Hangzhou Xixi Hospital
        • Contatto:
          • Rui Wu
          • Numero di telefono: +86 13655813566

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 80 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study population consists of adults aged 18 to 80 years with acute-on-chronic liver failure who are scheduled to receive artificial liver support for the first time at one of two participating hospitals in China. Eligible patients who provide written informed consent are enrolled prospectively. The two cohorts are defined by the treatment received in routine clinical care: plasma exchange plus double plasma molecular adsorption system (PE plus DPMAS) or plasma exchange plus continuous renal replacement therapy (PE plus CRRT). The study protocol does not assign treatment.

Descrizione

Inclusion Criteria:

  • Age 18 to 80 years, inclusive, regardless of sex.
  • Meets the protocol-defined AARC diagnostic criteria for acute-on-chronic liver failure, including all of the following:
  • Underlying chronic liver disease, including compensated cirrhosis, decompensated cirrhosis, or noncirrhotic chronic liver disease.
  • Acute hepatic decompensation within 4 weeks, presenting as jaundice and/or ascites and/or hepatic encephalopathy.
  • Serum total bilirubin of at least 5 mg/dL (85 micromol/L), together with either prothrombin activity of 40% or less or an international normalized ratio (INR) of at least 1.5.
  • Scheduled to receive artificial liver support for the first time, using either plasma exchange plus double plasma molecular adsorption system (PE plus DPMAS) or plasma exchange plus continuous renal replacement therapy (PE plus CRRT).
  • Able to understand the study purpose and procedures, willing and able to comply with study requirements, and personally provides written informed consent.
  • For the optional exploratory substudy only: agrees to provide blood and stool samples. Declining sample collection does not affect eligibility for the main cohort.

Exclusion Criteria:

  • Primary liver cancer or another malignancy.
  • Human immunodeficiency virus (HIV) infection.
  • Expected death within 24 to 48 hours, as independently determined by two investigators. If the investigators disagree, this criterion alone does not exclude the patient.
  • Pregnancy or breastfeeding.
  • Another serious illness associated with a life expectancy of less than 6 months, as judged by the investigator.
  • Current participation in another interventional clinical study.
  • Temporary or persistent lack of capacity to provide informed consent.
  • Any other circumstance that, in the investigator's judgment, makes the patient unsuitable for enrollment.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
PE Plus DPMAS

Adults with acute-on-chronic liver failure who receive plasma exchange (PE) in combination with the double plasma molecular adsorption system (DPMAS) as part of routine clinical care. The study protocol does not assign treatment.

PE Plus CRRT

Adults with acute-on-chronic liver failure who receive plasma exchange (PE) in combination with continuous renal replacement therapy (CRRT) as part of routine clinical care. The study protocol does not assign treatment.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
90-Day Transplant-Free Survival
Lasso di tempo: From enrollment through Day 90

The percentage of participants who are alive and have not undergone liver transplantation at Day 90 after enrollment. Death from any cause or liver transplantation is counted as an event, whichever occurs first.

From enrollment through Day 90

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
28-Day Transplant-Free Survival
Lasso di tempo: From enrollment through Day 28

The percentage of participants who are alive and have not undergone liver transplantation at Day 28 after enrollment. Death from any cause or liver transplantation is counted as an event, whichever occurs first.

From enrollment through Day 28
Occurrence of Liver Transplantation
Lasso di tempo: From enrollment through Day 90

The percentage of participants who undergo liver transplantation during follow-up. The date of transplantation is recorded.

From enrollment through Day 90
Change in Hepatic Encephalopathy Grade
Lasso di tempo: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment

Change in West Haven hepatic encephalopathy grade from baseline at each follow-up assessment, categorized as improvement, no change, or worsening.

Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
Reversal of Hepatorenal Syndrome
Lasso di tempo: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment

Percentage of participants with hepatorenal syndrome at baseline who meet the prespecified criteria for reversal at each follow-up assessment. Hepatorenal syndrome is diagnosed according to the International Club of Ascites criteria specified in the study protocol.

Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
Correction of Hyponatremia
Lasso di tempo: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment

Percentage of participants with hyponatremia at baseline who meet the prespecified correction criterion at each follow-up assessment, based on serum sodium measurements.

Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
Correction of Hyperkalemia
Lasso di tempo: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment

Percentage of participants with hyperkalemia at baseline who meet the prespecified correction criterion at each follow-up assessment, based on serum potassium measurements.

Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
Change From Baseline in SOFA Score
Lasso di tempo: Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment

Change in the Sequential Organ Failure Assessment (SOFA) score from baseline at each follow-up assessment. The total score ranges from 0 to 24, with higher scores indicating more severe organ dysfunction.

Baseline and Day 28, Day 90, Week 24, and Week 48 after enrollment
Relative Change in Total Bilirubin From Baseline During Serial Treatment and Follow-up
Lasso di tempo: Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment

elative change in total bilirubin from baseline at each subsequent treatment-related and follow-up assessment, using the prespecified calculation method. Treatment-related measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session. Both increases and decreases are recorded.

Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
Change in Blood Ammonia From Baseline
Lasso di tempo: Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment

Change in blood ammonia concentration from baseline at each postbaseline assessment, reported in micromoles per liter (μmol/L). Measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session, and at the scheduled follow-up assessments.

Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
Change in Serum Creatinine From Baseline
Lasso di tempo: Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment

Change in serum creatinine concentration from baseline at each postbaseline assessment, reported in micromoles per liter (μmol/L). Measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session, and at the scheduled follow-up assessments.

Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment
Change in INR From Baseline
Lasso di tempo: Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment

Change in the international normalized ratio (INR) from baseline at each postbaseline assessment. Measurements are obtained within 48 hours before the start and within 48 hours after the end of each artificial liver support session, and at the scheduled follow-up assessments.

Baseline; within 48 hours before the start and after the end of each artificial liver support session; and Day 28, Day 90, Week 24, and Week 48 after enrollment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

16 novembre 2026

Completamento primario (Stimato)

30 giugno 2028

Completamento dello studio (Stimato)

30 settembre 2028

Date di iscrizione allo studio

Primo inviato

3 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

7 novembre 2026

Primo Inserito (Effettivo)

12 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

7 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

There is no plan to share individual participant data with researchers outside the study team. Aggregate results may be reported in publications.

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi